We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
CONMED (CNMD) Q1 Earnings and Revenues Surpass Estimates
Read MoreHide Full Article
CONMED Corporation (CNMD - Free Report) reported first-quarter 2020 adjusted earnings per share of 51 cents, which beat the Zacks Consensus Estimate of 44 cents by 15.9%. However, the bottom line declined 10.5% from the year-ago quarter.
The New York-based medical products manufacturer reported revenues of $214 million, down 2% on a year-over-year basis and 0.7% at constant currency (cc). Nonetheless, the top line surpassed the Zacks Consensus Estimate by 2.6%.
Segment Details
Orthopedic Surgery
Revenues in the segment totaled $99.3 million, down 12.4% from the year-ago quarter.
On a domestic and on international basis Orthopedics revenues fell 18.2% and 8.7%, respectively, from the prior-year levels.
General Surgery
Revenues in the segment amounted to $114.7 million, up 9.2% year over year. Domestically, General Surgery sales improved 14% year over year but international sales declined 0.8%.
CONMED Corporation Price, Consensus and EPS Surprise
In the reported quarter, sales in the United States amounted to $118.8 million, up 1.5% year over year. International sales declined 6.1% to $95.2 million.
Margins
Gross profit in the quarter totaled $119.1 million, down 1.9% year over year. Per management, adjusted gross margin was 55.7%, contracting 10 bps.
Operating income came in at $13.2 million, up 13.2% year over year. Operating margin was 6.2%, up 90 bps year over year.
Financial Condition
Cash flow from operations for the three months ended Mar 31, 2020, was 3.7 million compared with ($3.9) million at the year-end 2019.
As of Mar 31, 2020, long-term debt at the end of the year was $772.6 million, up 2.3% sequentially.
2020 Guidance
Due to the uncertainty surrounding the extent and magnitude of the COVID-19 pandemic, management has decided to withdraw its previously announced 2020 guidance. It further added that it cannot furnish a reliable outlook at this moment.
Wrapping Up
CONMED exited the first quarter on a solid note, wherein earnings and revenues beat the respective estimates. The company’s core unit — General Surgery — continues to drive the top line. Expansion in margins is a positive.
The company generated around $6.2 million of sales from the Buffalo Filter buyout between Jan 1 and Feb 11.
Meanwhile, the company’s high long-term debt remains a concern. Further, its Orthopedic Surgery unit exhibited weak performance in the quarter under review. The company also witnessed a decline in international sales in the quarter. Additionally, CONMED operates in a highly competitive environment, especially with respect to the General Surgery business.
Zacks Rank
CONMED currently has a Zacks Rank #5 (Strong Sell).
The Zacks Consensus Estimate for Exact Sciences’s first-quarter 2020 revenues is pegged at $350.2 million, suggesting a whopping year-over-year improvement of 116.1%. The same for EPS stands at a loss of 60 cents, indicating an improvement of 9.1% from the prior-year quarter.
The Zacks Consensus Estimate for Aphria’s fourth-quarter fiscal 2020 revenues is $100.3 million, suggesting growth of 4.4% from the year-earlier reported figure.
The Zacks Consensus Estimate for Pacific Biosciences’ first-quarter 2020 revenues is pegged at $20.1 million, suggesting year-over-year improvement of 22.3%. The same for loss stands at 15 cents, indicating year-over-year improvement of 25%.
Looking for Stocks with Skyrocketing Upside?
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.
Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.
Image: Bigstock
CONMED (CNMD) Q1 Earnings and Revenues Surpass Estimates
CONMED Corporation (CNMD - Free Report) reported first-quarter 2020 adjusted earnings per share of 51 cents, which beat the Zacks Consensus Estimate of 44 cents by 15.9%. However, the bottom line declined 10.5% from the year-ago quarter.
The New York-based medical products manufacturer reported revenues of $214 million, down 2% on a year-over-year basis and 0.7% at constant currency (cc). Nonetheless, the top line surpassed the Zacks Consensus Estimate by 2.6%.
Segment Details
Orthopedic Surgery
Revenues in the segment totaled $99.3 million, down 12.4% from the year-ago quarter.
On a domestic and on international basis Orthopedics revenues fell 18.2% and 8.7%, respectively, from the prior-year levels.
General Surgery
Revenues in the segment amounted to $114.7 million, up 9.2% year over year.
Domestically, General Surgery sales improved 14% year over year but international sales declined 0.8%.
CONMED Corporation Price, Consensus and EPS Surprise
CONMED Corporation price-consensus-eps-surprise-chart | CONMED Corporation Quote
Sales by Geography
In the reported quarter, sales in the United States amounted to $118.8 million, up 1.5% year over year. International sales declined 6.1% to $95.2 million.
Margins
Gross profit in the quarter totaled $119.1 million, down 1.9% year over year. Per management, adjusted gross margin was 55.7%, contracting 10 bps.
Operating income came in at $13.2 million, up 13.2% year over year. Operating margin was 6.2%, up 90 bps year over year.
Financial Condition
Cash flow from operations for the three months ended Mar 31, 2020, was 3.7 million compared with ($3.9) million at the year-end 2019.
As of Mar 31, 2020, long-term debt at the end of the year was $772.6 million, up 2.3% sequentially.
2020 Guidance
Due to the uncertainty surrounding the extent and magnitude of the COVID-19 pandemic, management has decided to withdraw its previously announced 2020 guidance. It further added that it cannot furnish a reliable outlook at this moment.
Wrapping Up
CONMED exited the first quarter on a solid note, wherein earnings and revenues beat the respective estimates. The company’s core unit — General Surgery — continues to drive the top line. Expansion in margins is a positive.
The company generated around $6.2 million of sales from the Buffalo Filter buyout between Jan 1 and Feb 11.
Meanwhile, the company’s high long-term debt remains a concern. Further, its Orthopedic Surgery unit exhibited weak performance in the quarter under review. The company also witnessed a decline in international sales in the quarter. Additionally, CONMED operates in a highly competitive environment, especially with respect to the General Surgery business.
Zacks Rank
CONMED currently has a Zacks Rank #5 (Strong Sell).
Key Picks
Some better-ranked stocks in the broader medical space are Exact Sciences Corporation (EXAS - Free Report) , Aphria Inc. and Pacific Biosciences of California, Inc. (PACB - Free Report) , each carrying a Zacks Rank of 2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
The Zacks Consensus Estimate for Exact Sciences’s first-quarter 2020 revenues is pegged at $350.2 million, suggesting a whopping year-over-year improvement of 116.1%. The same for EPS stands at a loss of 60 cents, indicating an improvement of 9.1% from the prior-year quarter.
The Zacks Consensus Estimate for Aphria’s fourth-quarter fiscal 2020 revenues is $100.3 million, suggesting growth of 4.4% from the year-earlier reported figure.
The Zacks Consensus Estimate for Pacific Biosciences’ first-quarter 2020 revenues is pegged at $20.1 million, suggesting year-over-year improvement of 22.3%. The same for loss stands at 15 cents, indicating year-over-year improvement of 25%.
Looking for Stocks with Skyrocketing Upside?
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.
Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.
See the pot trades we're targeting>>